Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease
|
By LabMedica International staff writers Posted on 23 Nov 2021 |
|
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)
Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results in an enlarged thyroid.
Thyroid-stimulating hormone (TSH) receptor (TSHR) autoantibodies (TRAbs) are pathognomonic of GD and are detected in the serum of approximately 98% of patients with untreated GD. The specific and sensitive detection of thyroid-stimulating immunoglobulin (TSI) from other types of TRAbs is becoming increasingly important for the diagnostic accuracy of the Graves’ hyperthyroidism and of the extrathyroidal manifestations of GD.
Medical Laboratorians at the Shanghai Medical College (Shanghai, China) and their colleagues recruited 559 patients in the period between October 2020 and February 2021. There were 166 GD patients, 81 patients of whom were untreated GD, 393 patients with other thyroid diseases including 79 patients with Hashimoto's thyroiditis, 103 patients with thyroid nodules, 96 patients with hypothyroidism, 59 patients with nontoxic goiter, and 56 patients with thyroid cyst. In addition, 20 euthyroid healthy subjects were recruited as normal controls.
The team evaluated the analytical and clinical performance of two immunoassays for diagnosis of Graves’ disease (GD): the Immulite thyroid-stimulating immunoglobulin (TSI, Siemens Healthcare, Erlangen, Germany), and the Elecsys Anti-TSH receptor (TSHR), assay (Roche Diagnostics, Mannheim, Germany). The Immulite TSI assay is a chemiluminescence immunoassay with the clinical decision point of 0.55 IU/L. The Roche Elecsys Anti-TSHR assay is a competitive assay using electrochemiluminescence detection.
The investigators reported that the repeatability and intermediate imprecision coefficient of variation (CV%) of the TSI assay were 3.8% and 4.1% at 0.95 IU/L, and 3.5% and 3.6% at 19.5 IU/L, respectively. The assays were linear over a range 0.27–38.5 IU/L. There was a high correlation between the quantitative results of the two methods. The cut-off value obtained by ROC analysis for TSI assay was 0.7 IU/L with sensitivity of 93.7% and specificity of 85.1%. An overall qualitative agreement of 91.5% between two methods was observed. Among 44 patients with discordant qualitative results, the TSI assay provided more satisfactory results consistent with clinical diagnoses.
The authors concluded that the Immulite TSI assay specifically measured the pathogenic antibody of GD and exhibited excellent analytical performance. The Immulite TSI assay may be of great value for the clinical diagnosis of GD. The study was published on November 11, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Shanghai Medical College
Siemens Healthcare
Roche Diagnostics
Thyroid-stimulating hormone (TSH) receptor (TSHR) autoantibodies (TRAbs) are pathognomonic of GD and are detected in the serum of approximately 98% of patients with untreated GD. The specific and sensitive detection of thyroid-stimulating immunoglobulin (TSI) from other types of TRAbs is becoming increasingly important for the diagnostic accuracy of the Graves’ hyperthyroidism and of the extrathyroidal manifestations of GD.
Medical Laboratorians at the Shanghai Medical College (Shanghai, China) and their colleagues recruited 559 patients in the period between October 2020 and February 2021. There were 166 GD patients, 81 patients of whom were untreated GD, 393 patients with other thyroid diseases including 79 patients with Hashimoto's thyroiditis, 103 patients with thyroid nodules, 96 patients with hypothyroidism, 59 patients with nontoxic goiter, and 56 patients with thyroid cyst. In addition, 20 euthyroid healthy subjects were recruited as normal controls.
The team evaluated the analytical and clinical performance of two immunoassays for diagnosis of Graves’ disease (GD): the Immulite thyroid-stimulating immunoglobulin (TSI, Siemens Healthcare, Erlangen, Germany), and the Elecsys Anti-TSH receptor (TSHR), assay (Roche Diagnostics, Mannheim, Germany). The Immulite TSI assay is a chemiluminescence immunoassay with the clinical decision point of 0.55 IU/L. The Roche Elecsys Anti-TSHR assay is a competitive assay using electrochemiluminescence detection.
The investigators reported that the repeatability and intermediate imprecision coefficient of variation (CV%) of the TSI assay were 3.8% and 4.1% at 0.95 IU/L, and 3.5% and 3.6% at 19.5 IU/L, respectively. The assays were linear over a range 0.27–38.5 IU/L. There was a high correlation between the quantitative results of the two methods. The cut-off value obtained by ROC analysis for TSI assay was 0.7 IU/L with sensitivity of 93.7% and specificity of 85.1%. An overall qualitative agreement of 91.5% between two methods was observed. Among 44 patients with discordant qualitative results, the TSI assay provided more satisfactory results consistent with clinical diagnoses.
The authors concluded that the Immulite TSI assay specifically measured the pathogenic antibody of GD and exhibited excellent analytical performance. The Immulite TSI assay may be of great value for the clinical diagnosis of GD. The study was published on November 11, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Shanghai Medical College
Siemens Healthcare
Roche Diagnostics
Gold Member
Aspiration System
VACUSAFE
HPV Test
Allplex HPV28 Detection
Electrolyte Analyzer
BKE-B
Latest Immunology News
- Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
- Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
- Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
- New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
- Cell-Free Assay Detects Functional IgE for Food Allergy Diagnosis
- Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
- Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
- Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
- Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
- Airway Immune Signature May Predict Tuberculosis Progression Risk
- New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease
- Lung Immune Profiling Reveals Distinct Severe Pneumonia Subtypes
- Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
- Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Channels
Clinical Chemistry
view channel
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read more
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more
Molecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read more
Hematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more
Microbiology
view channel
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read more
Pathology
view channel
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
LumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more
